Department of Dermatology, Nippon Medical School.
J Nippon Med Sch. 2021 Jun 30;88(3):253-257. doi: 10.1272/jnms.JNMS.2021_88-312. Epub 2020 Aug 31.
We report a case of contact dermatitis caused by both efinaconazole, a topical triazole antifungal drug, and luliconazole, a topical imidazole antifungal drug. Positive patch test reactions were observed with efinaconazole and luliconazole. A patch test with lanoconazole also elicited a positive reaction. We hypothesized that structural similarity between luliconazole and lanoconazole led to cross-reaction, and that the dithiolane ring common to both drugs or the structure of the vinyl imidazole with a dithiolane ring could be the antigenic determinant. Since efinaconazole and luliconazole have no common structures, patients could be sensitized to both drugs separately. The antigenic determinant of efinaconazole is unknown. However, the chemical formula of ravuconazole, an oral triazole antifungal drug, is similar to that of efinaconazole. Clinicians should carefully consider potential cross-reactivity between these drugs.
我们报告了一例由外用三唑类抗真菌药物依氟康唑和外用咪唑类抗真菌药物卢立康唑引起的接触性皮炎。依氟康唑和卢立康唑的斑贴试验均呈阳性反应。用拉莫康唑进行斑贴试验也引起了阳性反应。我们假设卢立康唑和拉莫康唑之间的结构相似导致了交叉反应,而两种药物共有的二硫戊环或带有二硫戊环的乙烯基咪唑结构可能是抗原决定簇。由于依氟康唑和卢立康唑没有共同的结构,患者可能会分别对这两种药物产生过敏反应。依氟康唑的抗原决定簇尚不清楚。然而,口服三唑类抗真菌药物拉夫康唑的化学公式与依氟康唑相似。临床医生应仔细考虑这些药物之间的潜在交叉反应。